| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 02/27/2002 | CN1337962A Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| 02/27/2002 | CN1337959A 2-(2,6-dioxopiperidin-3-yl)-isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
| 02/27/2002 | CN1337952A 2,3,4,5-tetrahydro-1H-[1,4] benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors |
| 02/27/2002 | CN1337950A 2-oxoquinoline compounds and medicinal uses thereof |
| 02/27/2002 | CN1337949A Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid as TACE inhibitor |
| 02/27/2002 | CN1337947A Acetylenic sulfonamide thiol TACE inhibitors |
| 02/27/2002 | CN1337945A Alkynyl containing hydroxamic acid compounds as TACE inhibitors |
| 02/27/2002 | CN1337944A Acetylenic beta-sulfonamido and phosphinic acid amide hydroxamic acid as TACE inhibitors |
| 02/27/2002 | CN1337931A Retinoid antagonists and use thereof |
| 02/27/2002 | CN1337877A Method of preparing stable suspension of insoluble microparticles |
| 02/27/2002 | CN1337230A Application of Lavermit in preparing medicine for tetanic rachitis |
| 02/27/2002 | CN1079796C Novel N-7-heterocyclyl pyrrolo [2,3-D] pyridines and their use |
| 02/27/2002 | CN1079792C 酶抑制剂 Inhibitors |
| 02/27/2002 | CN1079791C Vitamin D. analogues |
| 02/27/2002 | CN1079677C Immunological tolerance-inducting agent |
| 02/26/2002 | US6350907 Matrix metalloprotease inhibitors |
| 02/26/2002 | US6350856 Cytokine suppressive anti-inflammatory drug binding protein |
| 02/26/2002 | US6350752 Modulating purine derivatives such as guanosine, inosine pranobex and 4-(3-(1,6-dihydro-6-oxo-9-purin-9-yl) -1-oxopropyl)amino)benzoic acid (ait-082); inducing in vivo production of heme oxygenase to reduce blood pressure; |
| 02/26/2002 | US6350744 Pyrmidine or pyridine derivatives; antiarthritic and antiinflammatory agents; cachexia treatment; interleukin and tumor necrosis factor inhibitors |
| 02/26/2002 | US6350735 Purine derivatives |
| 02/26/2002 | US6350590 Tolerogenic fragments of natural allergens |
| 02/26/2002 | US6350457 Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae |
| 02/26/2002 | CA2195094C Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases |
| 02/26/2002 | CA2160966C Piperidine derivatives; process for preparing them and compositions containing the same |
| 02/26/2002 | CA2057048C Vitamin d analogues |
| 02/26/2002 | CA2037709C Use of zinc calcium hydroxide, lecithin and pao as an adjuvant for antigen solutions, and antigen solutions treated with an adjuvant of this type |
| 02/26/2002 | CA2024672C Indole, benzofuran,and benzothiophene containing lipoxygenase inhibiting compounds |
| 02/21/2002 | WO2002014870A2 Use of antibodies against specific mhc-peptide complexes |
| 02/21/2002 | WO2002014511A2 Regulation of human p2y1-like g protein-coupled receptor |
| 02/21/2002 | WO2002014499A2 Claudin polypeptides |
| 02/21/2002 | WO2002014489A2 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof |
| 02/21/2002 | WO2002014481A1 Method of extensive culture of antigen-specific cytotoxic t cells |
| 02/21/2002 | WO2002014365A1 A new polypeptide-ras gtp activator protein 12 and the polynucleotide encoding it |
| 02/21/2002 | WO2002014362A2 A hepatitis c virus non-structural ns3/4a fusion gene |
| 02/21/2002 | WO2002014356A2 Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects |
| 02/21/2002 | WO2002014355A2 Novel mitogen activated kinase |
| 02/21/2002 | WO2002014349A2 Non-covalent inhibitors of urokinase and blood vessel formation |
| 02/21/2002 | WO2002014319A2 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 02/21/2002 | WO2002014317A2 Substituted pyrazoles |
| 02/21/2002 | WO2002014315A2 Substituted pyrazoles |
| 02/21/2002 | WO2002014314A2 Substituted pyrazoles |
| 02/21/2002 | WO2002014310A1 2-[5-AMINO-6-OXO-2-PHENYL-1,6-DIHYDRO-1-PYRIMIDYL]-N-[1-(2-[5-t-BUTYL-1,3,4-OXADIAZOLYL]CARBONYL)-2-(R,S)-METHYLPROPYL]ACETAMIDE HYDROCHLORIDE |
| 02/21/2002 | WO2002014285A1 Substituted imidazoles as tafia inhibitors |
| 02/21/2002 | WO2002014281A1 Pyridine derivatives as inhibitors of p38 |
| 02/21/2002 | WO2002014272A1 (thio)urea derivatives, process for their production and medicines containing the derivatives |
| 02/21/2002 | WO2002014271A1 Proline derivatives and use thereof as drugs |
| 02/21/2002 | WO2002014265A1 Novel 3-substituted urea derivatives and medicinal use thereof |
| 02/21/2002 | WO2002014262A1 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage |
| 02/21/2002 | WO2002014225A1 Ionization device which is mounted with gold pole or silver pole |
| 02/21/2002 | WO2002013866A2 Stimulating neutrophil function to treat inflammatory bowel disease |
| 02/21/2002 | WO2002013862A2 Method and composition for altering a b cell mediated pathology |
| 02/21/2002 | WO2002013861A2 Method and composition for altering a t cell mediated pathology |
| 02/21/2002 | WO2002013857A2 A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof |
| 02/21/2002 | WO2002013856A2 W/o emulsion adjuvant compositions for vaccines |
| 02/21/2002 | WO2002013855A2 Vaccines containing ribavirin and methods of use thereof |
| 02/21/2002 | WO2002013845A2 Inflammation related g-protein coupled receptor |
| 02/21/2002 | WO2002013828A1 A retroviral immunotherapy |
| 02/21/2002 | WO2002013824A1 Cyclopentyl modulators of chemokine receptor activity |
| 02/21/2002 | WO2002013821A1 Novel alicyclic imidazoles as h3 agents |
| 02/21/2002 | WO2002013816A1 Pharmaceutical composition |
| 02/21/2002 | WO2002013815A1 Oral drug composition containing a verapamil derivative as a drug-absorption promotor |
| 02/21/2002 | WO2002013814A1 Compositions and methods for inhibiting islet dysfunction and autoimmune disorders |
| 02/21/2002 | WO2002013813A1 Compositions and methods for inhibiting islet dysfunction and autoimmune disorders |
| 02/21/2002 | WO2002013763A2 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 02/21/2002 | WO2001090063A3 Prodrug of an ice inhibitor |
| 02/21/2002 | WO2001083698A3 Compositions and methods for inducing activation of dendritic cells |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001077149A3 Regulation of human cyslt2-like gpcr protein |
| 02/21/2002 | WO2001076626A3 Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants |
| 02/21/2002 | WO2001076561A3 Pharmaceutical compositions |
| 02/21/2002 | WO2001072960A3 Il-8 receptor antagonists |
| 02/21/2002 | WO2001072334A3 Methods for treating disease with antibodies to cxcr3 |
| 02/21/2002 | WO2001070807A3 G-protein associated molecules |
| 02/21/2002 | WO2001068802A3 Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
| 02/21/2002 | WO2001066747A8 Proteins named fctrx and nucleic acids encoding same |
| 02/21/2002 | WO2001062901A3 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| 02/21/2002 | WO2001056602A3 Cd40 ligand adjuvant for respiratory syncytial virus |
| 02/21/2002 | WO2001051008A3 Selective activation of a th1 or th2 lymphocyte regulated immune response |
| 02/21/2002 | WO2001046698A3 Tethered ligands and methods of use |
| 02/21/2002 | WO2001046397A3 Human kinases |
| 02/21/2002 | WO2001043775A3 Hydroxide-releasing agents as skin permeation enhancers |
| 02/21/2002 | WO2001043695A3 Peptide constructs for treating autoimmune and related diseases |
| 02/21/2002 | WO2001039803A3 Interleukin-1 muteins useful as vaccine adjuvants |
| 02/21/2002 | WO2001031005A3 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 02/21/2002 | WO2001030300A3 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 02/21/2002 | WO2000066148A9 Novel proteins |
| 02/21/2002 | US20020022729 Pyridylfuran and pyridylthiophene compounds |
| 02/21/2002 | US20020022646 Method for systhesizing leflunomide |
| 02/21/2002 | US20020022645 Administering benzofuran derivative for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase IV or Tumour Necrosis Factor |
| 02/21/2002 | US20020022637 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 02/21/2002 | US20020022635 For therapy of cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration |
| 02/21/2002 | US20020022628 Useful as metalloproteinase inhibitor; piperazino-sulfonamide or piperidino-sulfonamide compound |
| 02/21/2002 | US20020022620 Reverse-turn mimetics and methods relating thereto |
| 02/21/2002 | US20020022619 Administering to the mammal suffering from anxiety, depression and other disorders related to excessive corticotropin releasing factor an effective amount of tricyclic pyridine or pyrimidine derivatives |
| 02/21/2002 | US20020022218 Methods for the identification of compounds useful for the treatment of disease states medicated by prostaglandin D2 |
| 02/21/2002 | US20020022036 Administering high molecular weight urine isolate; anticancer, Aids therapy |
| 02/21/2002 | US20020022020 Induction lymphocyte tolerance |
| 02/21/2002 | US20020022017 Antitumor agents; fusion protein containing colony stimulanting factor |
| 02/21/2002 | DE10039199A1 Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen Combination preparations of ERß a selective estrogen and a SERM or antiestrogen |
| 02/21/2002 | DE10038639A1 New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism |